DUBLIN, Aug. 9, 2022 /PRNewswire/ -- The "Investigation Report on China's Shingles Vaccine Market 2022-2031" report has been added to ResearchAndMarkets.com's offering.
According to this market research, since the Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY19 million(US$2.85 million), and its annual sales volume reached nearly 12,000 doses. Therefore, the development prospects are quite good. According to the analysis, from 2022 to 2031, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck's Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase. The impact of COVID-19 on China's Shingles Vaccine market Sales volume and value of China's Shingles Vaccine 2020-2021
Competitive landscape of China's Shingles Vaccine market
Analysis on factors affecting the development of China's Shingles Vaccine market Prospect of China's Shingles Vaccine market from 2022 to 2031
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3.2 Analysis of Other Dosage Forms
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/9im8x6
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg